# Cormorant Asset Management, LP 13F Q2 2026: $2 billion

Cormorant Asset Management, LP reported $2 billion in 13F securities across 50 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Praxis Precision Medicines I at $214 million, 11.0% of the reported value. Since Q1 2026 it opened 13 new positions and exited 10.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,951,406,063
- Positions: 50
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1583977
- Form 13F file number: 028-15949
- CRD number: 167820
- Business address: 200 Clarendon Street 50th Floor, Boston, MA 02116
- SEC filing: [0001583977-26-000007](https://www.sec.gov/Archives/edgar/data/1583977/000158397726000007/0001583977-26-000007-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/cormorant-asset-management-lp-167820)

## Top 25 holdings by value

The largest of 50 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 640,000 | $214.3 million | -245,500 |
| [Bridgebio Oncology Therapeut](https://specstream.ai/data/institutional-holders/bridgebio-oncology-therapeut-107924102) | COM NEW | 17,878,594 | $136.2 million | No change |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 4,615,612 | $126.3 million | New |
| [Rapport Therapeutics Inc](https://specstream.ai/data/institutional-holders/rapport-therapeutics-inc-75383l102) | COM | 2,657,521 | $110.7 million | -300,000 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 6,000,000 | $109.9 million | +200,000 |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 2,510,000 | $102 million | -750,000 |
| [Eyepoint Inc](https://specstream.ai/data/institutional-holders/eyepoint-inc-30233g209) | COM NEW | 7,000,000 | $100.1 million | -1,265,000 |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 3,285,596 | $92.5 million | -663,645 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 675,000 | $90 million | -85,000 |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 750,000 | $73.1 million | -200,000 |
| [Bright Minds Biosciences Inc](https://specstream.ai/data/institutional-holders/bright-minds-biosciences-inc-10919w405) | COM NEW | 900,000 | $63.2 million | -159,331 |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 3,205,433 | $62.4 million | -1,275,000 |
| [Bioage Labs Inc](https://specstream.ai/data/institutional-holders/bioage-labs-inc-09077v100) | COM | 2,390,605 | $58.6 million | -500,000 |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 533,340 | $50.8 million | No change |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 3,978,229 | $45.7 million | +1,080,372 |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 550,000 | $41 million | -300,000 |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 1,300,000 | $40.6 million | -125,000 |
| [Biohaven LTD](https://specstream.ai/data/institutional-holders/biohaven-ltd-g1110e107) | COM | 2,610,000 | $38.8 million | +850,000 |
| [Agomab Therapeutics NV](https://specstream.ai/data/institutional-holders/agomab-therapeutics-nv-00860c102) | SPONSORED ADS | 2,465,348 | $32 million | No change |
| [MBX Biosciences Inc](https://specstream.ai/data/institutional-holders/mbx-biosciences-inc-55287l101) | COM | 550,000 | $30.4 million | -570,000 |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 2,106,000 | $27.5 million | New |
| [Olema Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/olema-pharmaceuticals-inc-68062p106) | COM | 2,150,000 | $26.9 million | -1,750,000 |
| [Damora Therapeutics Inc](https://specstream.ai/data/institutional-holders/damora-therapeutics-inc-36322q206) | COM NEW | 1,000,000 | $26 million | -525,000 |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 750,000 | $25.9 million | -250,000 |
| [Corbus Pharmaceuticals Hldgs](https://specstream.ai/data/institutional-holders/corbus-pharmaceuticals-hldgs-21833p301) | COM NEW | 2,344,971 | $22 million | No change |

## New positions in Q2 2026

13 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 4,615,612 | $126.3 million |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 2,106,000 | $27.5 million |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 225,000 | $20 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 400,000 | $18.8 million |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 50,000 | $13.3 million |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 550,000 | $12.1 million |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 150,000 | $7.6 million |
| [Ibio Inc](https://specstream.ai/data/institutional-holders/ibio-inc-451033708) | COM NEW | 3,570,000 | $6.2 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 370,000 | $4 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 1,250,000 | $3.8 million |
| [Odyssey Therapeutics Inc](https://specstream.ai/data/institutional-holders/odyssey-therapeutics-inc-67613t104) | COMMON STOCK | 175,000 | $3.3 million |
| [Boundless Bio Inc](https://specstream.ai/data/institutional-holders/boundless-bio-inc-10170a100) | COM | 1,000,000 | $2.5 million |
| [Quince Therapeutics Inc](https://specstream.ai/data/institutional-holders/quince-therapeutics-inc-22053a305) | COM | 5,498 | $100,009 |

## Positions exited in Q2 2026

10 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 1,050,000 | $41.7 million |
| [Maze Therapeutics Inc](https://specstream.ai/data/institutional-holders/maze-therapeutics-inc-578784100) | COM | 750,000 | $22.4 million |
| Ascendis Pharma A/S | SPONSORED ADR | 95,000 | $21.7 million |
| Terns Pharmaceuticals Inc | COM | 300,000 | $15.8 million |
| [Zura Bio LTD](https://specstream.ai/data/institutional-holders/zura-bio-ltd-g9ty5a101) | CLASS A ORD SHS | 1,450,000 | $8.6 million |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 50,000 | $8.5 million |
| Olema Pharmaceuticals Inc | COM (call) | 500,000 | $7.5 million |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 400,000 | $6.6 million |
| [Rallybio Corp](https://specstream.ai/data/institutional-holders/rallybio-corp-75120l209) | COM | 400,000 | $3.6 million |
| [Context Therapeutics Inc](https://specstream.ai/data/institutional-holders/context-therapeutics-inc-21077p108) | COM | 529,550 | $1.4 million |

## Also on SpecStream

- [Cormorant Asset Management, LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1583977/000158397726000007/0001583977-26-000007-index.htm)
- [Cormorant Asset Management, LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/cormorant-asset-management-lp-167820)
- [Largest 13F filers in Massachusetts](https://specstream.ai/data/institutional-holdings/state/massachusetts)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Boston, Massachusetts

- [Doctors' offices in Boston, Massachusetts](https://specstream.ai/data/businesses/doctors-offices/boston-massachusetts-united-states)
- [General dentistry practices in Boston, Massachusetts](https://specstream.ai/data/businesses/general-dentistry-practices/boston-massachusetts-united-states)
- [Irish pubs in Boston, Massachusetts](https://specstream.ai/data/businesses/irish-pubs/boston-massachusetts-united-states)
- [Mental health clinics in Boston, Massachusetts](https://specstream.ai/data/businesses/mental-health-clinics/boston-massachusetts-united-states)
- [Plastic and reconstructive surgery practices in Boston, Massachusetts](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/boston-massachusetts-united-states)
- [Restaurants in Boston, Massachusetts](https://specstream.ai/data/businesses/restaurants/boston-massachusetts-united-states)
